Rubella

Last updated

Rubella
Other namesGerman measles, three-day measles
Rash of rubella on back (crop).JPG
A rash due to rubella on a child's back. The area affected is similar to that of measles but the rash is less intensely red.
Specialty Infectious disease
Symptoms Rash, swollen lymph nodes, fever, sore throat, feeling tired [1] [2]
Complications Testicular swelling, inflammation of nerves, congenital rubella syndrome, miscarriage [1] [3]
Usual onset2 weeks after exposure [1]
Duration3 days [1]
Causes Rubella virus (spread through the air) [3] [4]
Diagnostic method Finding the virus in the blood, throat, or urine, antibody tests [1]
Prevention Rubella vaccine [3]
Treatment Supportive care [2]
Frequency17,865 cases (2022) [5]

Rubella, also known as German measles or three-day measles, [6] is an infection caused by the rubella virus. [3] This disease is often mild, with half of people not realizing that they are infected. [1] [7] A rash may start around two weeks after exposure and last for three days. [1] It usually starts on the face and spreads to the rest of the body. [1] The rash is sometimes itchy and is not as bright as that of measles. [1] Swollen lymph nodes are common and may last a few weeks. [1] A fever, sore throat, and fatigue may also occur. [1] [2] Joint pain is common in adults. [1] Complications may include bleeding problems, testicular swelling, encephalitis, and inflammation of nerves. [1] Infection during early pregnancy may result in a miscarriage or a child born with congenital rubella syndrome (CRS). [3] Symptoms of CRS manifest as problems with the eyes such as cataracts, deafness, as well as affecting the heart and brain. [3] Problems are rare after the 20th week of pregnancy. [3]

Contents

Rubella is usually spread from one person to the next through the air via coughs of people who are infected. [3] [4] People are infectious during the week before and after the appearance of the rash. [1] Babies with CRS may spread the virus for more than a year. [1] Only humans are infected. [3] Insects do not spread the disease. [1] Once recovered, people are immune to future infections. [3] Testing is available that can verify immunity. [3] Diagnosis is confirmed by finding the virus in the blood, throat, or urine. [1] Testing the blood for antibodies may also be useful. [1]

Rubella is preventable with the rubella vaccine with a single dose being more than 95% effective. [3] Often it is given in combination with the measles vaccine and mumps vaccine, known as the MMR vaccine. [1] When some, but less than 80%, of a population is vaccinated, more women may reach childbearing age without developing immunity by infection or vaccination, thus possibly raising CRS rates. [3] Once infected there is no specific treatment. [2]

Rubella is a common infection in many areas of the world. [2] Each year about 100,000 cases of congenital rubella syndrome occur. [3] Rates of disease have decreased in many areas as a result of vaccination. [2] [7] There are ongoing efforts to eliminate the disease globally. [3] In April 2015, the World Health Organization declared the Americas free of rubella transmission. [8] [9] The name "rubella" is from Latin and means little red. [1] It was first described as a separate disease by German physicians in 1814, resulting in the name "German measles". [1]

Signs and symptoms

Young boy displaying the characteristic maculopapular rash of rubella 10145 lores.jpg
Young boy displaying the characteristic maculopapular rash of rubella
Generalized rash on the abdomen due to rubella Rubella.jpg
Generalized rash on the abdomen due to rubella

Rubella has symptoms similar to those of flu. However, the primary symptom of rubella virus infection is the appearance of a rash (exanthem) on the face which spreads to the trunk and limbs and usually fades after three days, which is why it is often referred to as three-day measles. The facial rash usually clears as it spreads to other parts of the body. Other symptoms include low-grade fever, swollen glands (sub-occipital and posterior cervical lymphadenopathy), joint pains, headache, and conjunctivitis. [11]

The swollen glands or lymph nodes can persist for up to a week and the fever rarely rises above 38 °C (100.4 °F). The rash of rubella is typically pink or light red. The rash causes itching and often lasts for about three days. The rash disappears after a few days with no staining or peeling of the skin. When the rash clears up, the skin might shed in very small flakes where the rash covered it. Forchheimer spots occur in 20% of cases and are characterized by small, red papules on the area of the soft palate. [12]

Rubella can affect anyone of any age. Adult females are particularly prone to arthritis and joint pains. [13]

In children, rubella normally causes symptoms that last two days and include:

In older children and adults, additional symptoms may be present, including[ citation needed ]

Severe complications of rubella include:

Coryza in rubella may convert to pneumonia, either direct viral pneumonia or secondary bacterial pneumonia, and bronchitis (either viral bronchitis or secondary bacterial bronchitis). [16]

Congenital rubella syndrome

Child with cataracts in both eyes due to congenital rubella syndrome Cataracts due to Congenital Rubella Syndrome (CRS) PHIL 4284 lores.jpg
Child with cataracts in both eyes due to congenital rubella syndrome

Rubella can cause congenital rubella syndrome in the newborn, this being the most severe sequela of rubella. The syndrome (CRS) follows intrauterine infection by the rubella virus and comprises cardiac, cerebral, ophthalmic, and auditory defects. [17] It may also cause prematurity, low birth weight, neonatal thrombocytopenia, anemia, and hepatitis. The risk of major defects in organogenesis is highest for infection in the first trimester. CRS is the main reason a vaccine for rubella was developed. [18]

80–90% of mothers who contract rubella within the critical first trimester have either a miscarriage or a stillborn baby. [11] If the fetus survives the infection, it can be born with severe heart disorders (patent ductus arteriosus being the most common), blindness, deafness, or other life-threatening organ disorders. The skin manifestations are called "blueberry muffin lesions". [18] For these reasons, rubella is included in the TORCH complex of perinatal infections. [19] [20]

About 100,000 cases of this condition occur each year. [3]

Cause

Transmission electron micrograph of rubella viruses Rubella virus TEM B82-0203 lores.jpg
Transmission electron micrograph of rubella viruses

The disease is caused by the rubella virus, in the genus Rubivirus from the family Matonaviridae, [21] that is enveloped and has a single-stranded RNA genome. [22] The virus is transmitted by the respiratory route and replicates in the nasopharynx and lymph nodes. The virus is found in the blood 5 to 7 days after infection and spreads throughout the body. The virus has teratogenic properties and is capable of crossing the placenta and infecting the fetus where it stops cells from developing or destroys them. [11] During this incubation period, the patient is contagious typically for about one week before he/she develops a rash and for about one week thereafter. [1]

Increased susceptibility to infection might be inherited as there is some indication that HLA-A1 or factors surrounding A1 on extended haplotypes are involved in virus infection or non-resolution of the disease. [23] [24]

Diagnosis

Rubella virus specific IgM antibodies are present in people recently infected by rubella virus, but these antibodies can persist for over a year, and a positive test result needs to be interpreted with caution. [25] The presence of these antibodies along with, or a short time after, the characteristic rash confirms the diagnosis. [26]

Prevention

Rubella infections are prevented by active immunization programs using live attenuated virus vaccines. Two live attenuated virus vaccines, RA 27/3 and Cendehill strains, were effective in the prevention of adult disease. However, their use in prepubertal females did not produce a significant fall in the overall incidence rate of CRS in the UK. Reductions were only achieved by immunisation of all children. [27]

The vaccine is now usually given as part of the MMR vaccine. The WHO recommends the first dose be given at 12 to 18 months of age with a second dose at 36 months. Pregnant women are usually tested for immunity to rubella early on. Women found to be susceptible are not vaccinated until after the baby is born because the vaccine contains live virus. [28]

The immunisation program has been quite successful. Cuba declared the disease eliminated in the 1990s, and in 2004 the Centers for Disease Control and Prevention announced that both the congenital and acquired forms of rubella had been eliminated from the United States. [29] [30] The World Health Organization declared Australia rubella free in October 2018. [31]

Screening for rubella susceptibility by history of vaccination or by serology is recommended in the United States for all women of childbearing age at their first preconception counseling visit to reduce incidence of congenital rubella syndrome (CRS). [32] It is recommended that all susceptible non-pregnant women of childbearing age should be offered rubella vaccination. [32] Due to concerns about possible teratogenicity, use of MMR vaccine is not recommended during pregnancy. [32] Instead, susceptible pregnant women should be vaccinated as soon as possible in the postpartum period. [32]

In susceptible people passive immunization, in the form of polyclonal immunoglobulins, appears effective up to the fifth day post-exposure. [33]

Treatment

There is no specific treatment for rubella; however, management is a matter of responding to symptoms to diminish discomfort. Treatment of newborn babies is focused on management of the complications. Congenital heart defects and cataracts can be corrected by direct surgery. [13] [34]

Management for ocular congenital rubella syndrome (CRS) is similar to that for age-related macular degeneration, including counseling, regular monitoring, and the provision of low vision devices, if required. [35]

Prognosis

Rubella infection of children and adults is usually mild, self-limiting, and often asymptomatic. The prognosis in children born with CRS is poor. [36]

Epidemiology

Rubella occurs worldwide. The virus tends to peak during the spring in countries with temperate climates. Before the vaccine against rubella was introduced in 1969, widespread outbreaks usually occurred every 6–9 years in the United States and 3–5 years in Europe, mostly affecting children in the 5–9 year old age group. [37] Since the introduction of vaccine, occurrences have become rare in those countries with high uptake rates.[ citation needed ]

Vaccination has interrupted the transmission of rubella in the Americas: no endemic case has been observed since February 2009. [38] Vaccination is still strongly recommended as the virus could be reintroduced from other continents should vaccination rates in the Americas drop. [39] During the epidemic in the US between 1962 and 1965, rubella virus infections during pregnancy were estimated to have caused 30,000 stillbirths and 20,000 children to be born impaired or disabled as a result of CRS. [40] [41] Universal immunisation producing a high level of herd immunity is important in the control of epidemics of rubella. [42]

In the UK, there remains a large population of men susceptible to rubella who have not been vaccinated. Outbreaks of rubella occurred amongst many young men in the UK in 1993 and in 1996 the infection was transmitted to pregnant women, many of whom were immigrants and were susceptible. Outbreaks still arise, usually in developing countries where the vaccine is not as accessible. [43] The complications encountered in pregnancy from rubella infection (miscarriage, fetal death, congenital rubella syndrome) are more common in Africa and Southeast Asia at a rate of 121 per 100,000 live births compared to 2 per 100,000 live births in the Americas and Europe. [44]

In Japan, 15,000 cases of rubella and 43 cases of congenital rubella syndrome were reported to the National Epidemiological Surveillance of Infectious Diseases between October 15, 2012, and March 2, 2014, during the 2012–13 rubella outbreak in Japan. They mainly occurred in men aged 31–51 and young adults aged 24–34. [45]

History

Rubella was first described in the mid-eighteenth century. German physician and chemist, Friedrich Hoffmann, made the first clinical description of rubella in 1740, [46] which was confirmed by de Bergen in 1752 and Orlow in 1758. [47]

In 1814, George de Maton first suggested that it be considered a disease distinct from both measles and scarlet fever. All these physicians were German, and the disease was known as Rötheln (contemporary German Röteln). (Rötlich means "reddish" or "pink" in German.) The fact that three Germans described it led to the common name of "German measles." [48] Henry Veale, an English Royal Artillery surgeon, described an outbreak in India. He coined the name "rubella" (from the Latin word, meaning "little red") in 1866. [46] [49] [50] [51]

It was formally recognised as an individual entity in 1881, at the International Congress of Medicine in London. [52] In 1914, Alfred Fabian Hess theorised that rubella was caused by a virus, based on work with monkeys. [53] In 1938, Hiro and Tosaka confirmed this by passing the disease to children using filtered nasal washings from acute cases. [50]

In 1940, there was a widespread epidemic of rubella in Australia. Subsequently, ophthalmologist Norman McAllister Gregg found 78 cases of congenital cataracts in infants and 68 of them were born to mothers who had caught rubella in early pregnancy. [49] [50] Gregg published an account, Congenital Cataract Following German Measles in the Mother, in 1941. He described a variety of problems now known as congenital rubella syndrome (CRS) and noticed that the earlier the mother was infected, the worse the damage was. Since no vaccine was yet available, some popular magazines promoted the idea of "German measles parties" for infected children to spread the disease to other children (especially girls) to immunize them for life and protect them from later catching the disease when pregnant. [54] The virus was isolated in tissue culture in 1962 by two separate groups led by physicians Paul Douglas Parkman and Thomas Huckle Weller. [49] [51]

There was a pandemic of rubella between 1962 and 1965, starting in Europe and spreading to the United States. [51] In the years 1964–65, the United States had an estimated 12.5 million rubella cases (1964–1965 rubella epidemic). This led to 11,000 miscarriages or therapeutic abortions and 20,000 cases of congenital rubella syndrome. Of these, 2,100 died as neonates, 12,000 were deaf, 3,580 were blind, and 1,800 were intellectually disabled. In New York alone, CRS affected 1% of all births. [55] [56]

In 1967, the molecular structure of rubella was observed under electron microscopy using antigen-antibody complexes by Jennifer M. Best, June Almeida, J E Banatvala and A P Waterson. [57] [58]

In 1969, a live attenuated virus vaccine was licensed. [50] In the early 1970s, a triple vaccine containing attenuated measles, mumps and rubella (MMR) viruses was introduced. [51] By 2006, confirmed cases in the Americas had dropped below 3000 a year. However, a 2007 outbreak in Argentina, Brazil, and Chile pushed the cases to 13,000 that year. [8]

Eradication efforts

On January 22, 2014, the World Health Organization (WHO) and the Pan American Health Organization declared and certified Colombia free of rubella and became the first Latin American country to eliminate the disease within its borders. [59] [60] On April 29, 2015, the Americas became the first WHO region to officially eradicate the disease. The last non-imported cases occurred in 2009 in Argentina and Brazil. The Pan American Health Organization director remarked, "The fight against rubella has taken more than 15 years, but it has paid off with what I believe will be one of the most important pan-American public health achievements of the 21st Century." [61] The declaration was made after 165 million health records and genetically confirming that all recent cases were caused by known imported strains of the virus. Rubella is still common in some regions of the world and Susan E. Reef, team lead for rubella at the CDC's global immunization division, who joined in the announcement, said there was no chance it would be eradicated worldwide before 2020. [8] Rubella is the third disease to be eliminated from the Western Hemisphere with vaccination after smallpox and polio. [8] [9]

Etymology

From "rubrum" the Latin for "red", rubella means "reddish and small". "German" measles derives from "germanus" which means "similar" in this context. [62]

The name rubella is sometimes confused with rubeola, an alternative name for measles in English-speaking countries; the diseases are unrelated. [63] [64] In some other European languages, like Spanish, rubella and rubeola are synonyms, and rubeola is not an alternative name for measles. Thus, in Spanish, rubeola refers to rubella and sarampión refers to measles. [65] [66]

See also

Related Research Articles

<span class="mw-page-title-main">Measles</span> Viral disease affecting humans

Measles is a highly contagious, vaccine-preventable infectious disease caused by measles virus. Symptoms usually develop 10–12 days after exposure to an infected person and last 7–10 days. Initial symptoms typically include fever, often greater than 40 °C (104 °F), cough, runny nose, and inflamed eyes. Small white spots known as Koplik's spots may form inside the mouth two or three days after the start of symptoms. A red, flat rash which usually starts on the face and then spreads to the rest of the body typically begins three to five days after the start of symptoms. Common complications include diarrhea, middle ear infection (7%), and pneumonia (6%). These occur in part due to measles-induced immunosuppression. Less commonly seizures, blindness, or inflammation of the brain may occur. Other names include morbilli, rubeola, red measles, and English measles. Both rubella, also known as German measles, and roseola are different diseases caused by unrelated viruses.

<span class="mw-page-title-main">Mumps</span> Human disease caused by paramyxovirus

Mumps is a highly contagious viral disease caused by the mumps virus. Initial symptoms of mumps are non-specific and include fever, headache, malaise, muscle pain, and loss of appetite. These symptoms are usually followed by painful swelling around the side of the face, which is the most common symptom of a mumps infection. Symptoms typically occur 16 to 18 days after exposure to the virus. About one third of people with a mumps infection do not have any symptoms (asymptomatic).

<span class="mw-page-title-main">MMR vaccine</span> Combined vaccine against measles, mumps, and rubella

The MMR vaccine is a vaccine against measles, mumps, and rubella, abbreviated as MMR. The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least four weeks between the doses. After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended for those who do not have evidence of immunity, those with well-controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection.

<span class="mw-page-title-main">Herd immunity</span> Concept in epidemiology

Herd immunity is a form of indirect protection that applies only to contagious diseases. It occurs when a sufficient percentage of a population has become immune to an infection, whether through previous infections or vaccination, that the communicable pathogen cannot maintain itself in the population, its low incidence thereby reducing the likelihood of infection for individuals who lack immunity.

<span class="mw-page-title-main">Congenital rubella syndrome</span> Medical condition

Congenital rubella syndrome (CRS) occurs when a human fetus is infected with the rubella virus via maternal-fetal transmission and develops birth defects. The most common congenital defects affect the ophthalmologic, cardiac, auditory, and neurologic systems.

<span class="mw-page-title-main">Fifth disease</span> Red rash due to infection with parvovirus B19

Fifth disease, also known as erythema infectiosum and slapped cheek syndrome, is a common and contagious disease caused by infection with parvovirus B19. This virus was discovered in 1975 and can cause other diseases besides fifth disease. Fifth disease typically presents as a rash and is most common in children. While parvovirus B19 can affect people of all ages, only two out of ten individuals will present with symptoms.

<span class="mw-page-title-main">Childhood immunizations in the United States</span>

The schedule for childhood immunizations in the United States is published by the Centers for Disease Control and Prevention (CDC). The vaccination schedule is broken down by age: birth to six years of age, seven to eighteen, and adults nineteen and older. Childhood immunizations are key in preventing diseases with epidemic potential.

The MMRV vaccine is a combination vaccine which combines the attenuated virus measles, mumps, rubella, and varicella (chickenpox). The MMRV vaccine has similar immunogenicity and overall safety profiles to the MMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age.

<span class="mw-page-title-main">Varicella vaccine</span> Vaccine to prevent chickenpox

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine are more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin. Another vaccine, known as zoster vaccine, is used to prevent diseases caused by the same virus – the varicella zoster virus.

Immunization during pregnancy is the administration of a vaccine to a pregnant individual. This may be done either to protect the individual from disease or to induce an antibody response, such that the antibodies cross the placenta and provide passive immunity to the infant after birth. In many countries, including the US, Canada, UK, Australia and New Zealand, vaccination against influenza, COVID-19 and whooping cough is routinely offered during pregnancy.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.

<span class="mw-page-title-main">Eradication of infectious diseases</span> Elimination of a disease from all hosts

The eradication of infectious diseases is the reduction of the prevalence of an infectious disease in the global host population to zero.

<span class="mw-page-title-main">Chickenpox</span> Human viral disease

Chickenpox, also known as varicella, is a highly contagious, vaccine-preventable disease caused by the initial infection with varicella zoster virus (VZV), a member of the herpesvirus family. The disease results in a characteristic skin rash that forms small, itchy blisters, which eventually scab over. It usually starts on the chest, back, and face. It then spreads to the rest of the body. The rash and other symptoms, such as fever, tiredness, and headaches, usually last five to seven days. Complications may occasionally include pneumonia, inflammation of the brain, and bacterial skin infections. The disease is usually more severe in adults than in children.

<span class="mw-page-title-main">Measles vaccine</span> Vaccine used to prevent measles

Measles vaccine protects against becoming infected with measles. Nearly all of those who do not develop immunity after a single dose develop it after a second dose. When the rate of vaccination within a population is greater than 92%, outbreaks of measles typically no longer occur; however, they may occur again if the rate of vaccination decreases. The vaccine's effectiveness lasts many years. It is unclear if it becomes less effective over time. The vaccine may also protect against measles if given within a couple of days after exposure to measles.

<span class="mw-page-title-main">Rubella vaccine</span> Vaccine used to prevent rubella

Rubella vaccine is a vaccine used to prevent rubella. Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of rubella or congenital rubella syndrome. When there is a low level of childhood immunization in a population it is possible for rates of congenital rubella to increase as more women make it to child-bearing age without either vaccination or exposure to the disease. Therefore, it is important for more than 80% of people to be vaccinated. By introducing rubella containing vaccines, rubella has been eradicated in 81 nations, as of mid-2020.

<span class="mw-page-title-main">Blueberry muffin baby</span> Purplish skin bumps on a newborn due to overproduction of blood

Blueberry muffin baby, also known as extramedullary hematopoiesis, describes a newborn baby with multiple purpura, associated with several non-cancerous and cancerous conditions in which extra blood is produced in the skin. The bumps range from 1-7 mm, do not blanch and have a tendency to occur on the head, neck and trunk. They often fade by three to six weeks after birth, leaving brownish marks. When due to a cancer, the bumps tend to be fewer, firmer and larger.

<span class="mw-page-title-main">Epidemiology of measles</span>

Measles is extremely contagious, but surviving the infection results in lifelong immunity, so its continued circulation in a community depends on the generation of susceptible hosts by birth of children. In communities which generate insufficient new hosts the disease will die out. This concept was first recognized by Bartlett in 1957, who referred to the minimum number supporting measles as the critical community size (CCS). Analysis of outbreaks in island communities suggested that the CCS for measles is c. 250,000. Due to the development of vaccination against measles, the world has seen a 99% decrease in measles related cases compared cases before the vaccine was developed.

<span class="mw-page-title-main">Neonatal infection</span> Human disease

Neonatal infections are infections of the neonate (newborn) acquired during prenatal development or within the first four weeks of life. Neonatal infections may be contracted by mother to child transmission, in the birth canal during childbirth, or after birth. Neonatal infections may present soon after delivery, or take several weeks to show symptoms. Some neonatal infections such as HIV, hepatitis B, and malaria do not become apparent until much later. Signs and symptoms of infection may include respiratory distress, temperature instability, irritability, poor feeding, failure to thrive, persistent crying and skin rashes.

Vaccination in Bangladesh includes all aspects of vaccination in Bangladesh.

The 1962–1965 rubella epidemic was an outbreak of rubella across Europe and the United States. The Rubella virus, also known as the German measles, is a single-stranded RNA virus from the family Togaviridae and genus Rubivirus. Typically, the virus is transmitted via droplets, such as coughing or sneezing, however, congenital rubella can be passed on from a pregnant woman to her fetus. The disease itself is fairly mild, usually presenting with a rash on the face and general sickness symptoms, such as coughing, fever, and fatigue, however, the real danger lies in Rubella infections in women who are pregnant. Pregnant women with Rubella are at risk of having a miscarriage or having a baby born with multiple birth defects due to Congenital rubella syndrome.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Atkinson W (2011). Epidemiology and Prevention of Vaccine-Preventable Diseases (12 ed.). Public Health Foundation. pp. 301–323. ISBN   978-0-9832631-3-5. Archived from the original on 2017-05-01. Retrieved 2017-05-05.
  2. 1 2 3 4 5 6 McLean H (2014). "3 Infectious Diseases Related To Travel". CDC health information for international travel 2014 : the yellow book. Oup USA. ISBN   978-0-19-994849-9. Archived from the original on 2015-04-24 – via cdc.gov.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA (7 January 2015). "Rubella". Lancet. 385 (9984): 2297–307. doi:10.1016/S0140-6736(14)60539-0. PMC   4514442 . PMID   25576992.
  4. 1 2 "Rubella (German Measles, Three-Day Measles)". CDC.gov. US: Centers for Disease Control and Prevention. December 17, 2014. Archived from the original on 2 April 2015. Retrieved 30 March 2015.
  5. ↑ "Rubella". World Health Organization (WHO). 2024-05-14. Retrieved 2024-10-02.
  6. ↑ Neighbors M, Tannehill-Jones R (2010). "Childhood diseases and disorders". Human diseases (3rd ed.). Clifton Park, New York: Delmar, Cengage Learning. pp. 457–79. ISBN   978-1-4354-2751-8.
  7. 1 2 "Rubella vaccines: WHO position paper" (PDF). Wkly Epidemiol Rec. 86 (29): 301–16. 15 July 2011. PMID   21766537. Archived (PDF) from the original on 5 June 2015.
  8. 1 2 3 4 Donald G. McNeil Jr. (April 29, 2015). "Rubella Has Been Eliminated From the Americas, Health Officials Say". The New York Times. Archived from the original on May 1, 2015. Retrieved April 30, 2015.
  9. 1 2 "Americas region is declared the world's first to eliminate rubella". PAHO.org. Pan American Health Organization, World Health Organization. 29 April 2015. Archived from the original on 18 May 2015. Retrieved 6 May 2015.
  10. ↑ "Public Health Image Library (PHIL)". cdc.gov. Center for Disease Control and Prevention. 1966. Archived from the original on 15 March 2015. Retrieved 24 May 2015.
  11. 1 2 3 Edlich RF, Winters KL, Long WB, Gubler KD (2005). "Rubella and congenital rubella (German measles)". J Long Term Eff Med Implants. 15 (3): 319–28. doi:10.1615/JLongTermEffMedImplants.v15.i3.80. PMID   16022642.
  12. ↑ Kliegman R, Nelson WE, Jenson HB, Marcdante KJ, Behrman RE (2006). Nelson Essentials of Pediatrics. Elsevier Health Sciences. p. 467. ISBN   978-1-4160-0159-1.
  13. 1 2 3 4 Kasper DL, Fauci AS, Hauser SL, Longo DL, Larry Jameson J, Loscalzo J (2018-02-06). "Rubella (German Measles)". Harrison's principles of internal medicine (20th ed.). New York. ISBN   978-1-259-64404-7. OCLC   990065894.{{cite book}}: CS1 maint: location missing publisher (link)
  14. ↑ "Rubella (German Measles)". kidshealth.org. Archived from the original on 2013-10-06.
  15. ↑ "Diseases and Conditions: Rubella: Complications". mayoclinic.org. Mayo Foundation for Medical Education and Research. 13 May 2015. Archived from the original on 18 May 2015.
  16. ↑ Michael M (1908). "Rubella: Report of Epidemic of Eighty Cases". In Treat E (ed.). Archives of Pediatrics. p. 604. Archived from the original on 2015-11-25.
  17. ↑ Atreya CD, Mohan KV, Kulkarni S (2004). "Rubella virus and birth defects: molecular insights into the viral teratogenesis at the cellular level". Birth Defects Res. A. 70 (7): 431–7. doi:10.1002/bdra.20045. PMID   15259032. Archived from the original on 2020-08-06. Retrieved 2019-07-05.
  18. 1 2 De Santis M, Cavaliere AF, Straface G, Caruso A (2006). "Rubella infection in pregnancy". Reprod. Toxicol. 21 (4): 390–8. doi:10.1016/j.reprotox.2005.01.014. PMID   16580940.
  19. ↑ "TORCH Syndrome". NORD (National Organization for Rare Disorders). Archived from the original on 2017-06-27. Retrieved 2022-05-18.
  20. ↑ Epps RE, Pittelkow MR, Su WP (1995-06-01). "TORCH syndrome". Seminars in Dermatology. 14 (2): 179–186. doi:10.1016/s1085-5629(05)80016-1. ISSN   0278-145X. PMID   7640200. Archived from the original on 2023-01-13. Retrieved 2022-05-18.
  21. ↑ Walker PJ, Siddell SG, Lefkowitz EJ, Mushegian AR, Dempsey DM, Dutilh BE, et al. (September 2019). "Changes to virus taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2019)". Arch. Virol. 164 (9): 2417–2429. doi: 10.1007/s00705-019-04306-w . PMID   31187277.
  22. ↑ Frey TK (1994). "Molecular biology of rubella virus". Advances in Virus Research, Volume 44. Vol. 44. pp. 69–160. doi:10.1016/S0065-3527(08)60328-0. ISBN   978-0-12-039844-7. PMC   7131582 . PMID   7817880.{{cite book}}: |journal= ignored (help)
  23. ↑ Forrest JM, Turnbull FM, Sholler GF, et al. (2002). "Gregg's congenital rubella patients 60 years later". Med. J. Aust. 177 (11–12): 664–7. doi:10.5694/j.1326-5377.2002.tb05003.x. PMID   12463994. S2CID   36212779. Archived from the original on 2008-08-30.
  24. ↑ Honeyman MC, Dorman DC, Menser MA, Forrest JM, Guinan JJ, Clark P (February 1975). "HL-A antigens in congenital rubella and the role of antigens 1 and 8 in the epidemiology of natural rubella". Tissue Antigens. 5 (1): 12–8. doi:10.1111/j.1399-0039.1975.tb00520.x. PMID   1138435.
  25. ↑ Best JM (2007). "Rubella". Semin Fetal Neonatal Med. 12 (3): 182–92. doi:10.1016/j.siny.2007.01.017. PMID   17337363.
  26. ↑ Stegmann BJ, Carey JC (2002). "TORCH Infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections". Curr Women's Health Rep. 2 (4): 253–8. PMID   12150751.
  27. ↑ Robertson SE, Cutts FT, Samuel R, Diaz-Ortega JL (1997). "Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella". Bulletin of the World Health Organization. 75 (1): 69–80. PMC   2486979 . PMID   9141752.
  28. ↑ Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L (1998). "Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 47 (RR-8): 1–57. PMID   9639369. Archived from the original on 2009-09-18.
  29. ↑ Dayan GH, Castillo-Solórzano C, Nava M, et al. (2006). "Efforts at rubella elimination in the United States: the impact of hemispheric rubella control". Clin. Infect. Dis. 43 (Suppl 3): S158–63. doi: 10.1086/505949 . PMID   16998776.
  30. ↑ Centers for Disease Control and Prevention (CDC) (2005). "Elimination of rubella and congenital rubella syndrome—United States, 1969–2004". MMWR Morb. Mortal. Wkly. Rep. 54 (11): 279–82. PMID   15788995. Archived from the original on 2007-10-01.
  31. ↑ Davey M (31 October 2018). "Rubella's elimination from Australia 'shows vaccinations work'". the Guardian. Archived from the original on 31 October 2018. Retrieved 31 October 2018.
  32. 1 2 3 4 Health Care Guideline: Routine Prenatal Care. Fourteenth Edition. Archived 2012-06-24 at the Wayback Machine By the Institute for Clinical Systems Improvement July 2010.
  33. ↑ Young MK, Cripps AW, Nimmo GR, van Driel ML (9 September 2015). "Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome". Cochrane Database of Systematic Reviews. 2015 (9): 2. doi:10.1002/14651858.CD010586.pub2. hdl: 10072/99129 . PMC   8761358 . PMID   26350479.
  34. ↑ Khandekar R, Sudhan A, Jain BK, Shrivastav K, Sachan R (2007). "Pediatric cataract and surgery outcomes in Central India: a hospital based study". Indian J Med Sci. 61 (1): 15–22. doi: 10.4103/0019-5359.29593 . hdl: 1807/54989 . PMID   17197734. Archived from the original on 2020-08-06. Retrieved 2019-07-05.
  35. ↑ Weisinger HS, Pesudovs K (2002). "Optical complications in congenital rubella syndrome". Optometry. 73 (7): 418–24. PMID   12365660.
  36. ↑ Freij BJ, South MA, Sever JL (1988). "Maternal rubella and the congenital rubella syndrome". Clin Perinatol. 15 (2): 247–57. doi:10.1016/S0095-5108(18)30710-3. PMID   3288422.
  37. ↑ Reef SE, Frey TK, Theall K, et al. (2002). "The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention". JAMA . 287 (4): 464–72. doi: 10.1001/jama.287.4.464 . PMID   11798368.
  38. ↑ "Rubella Watch". PAHO.org. Pan American Health Organization, World Health Organization. Archived from the original on 2011-06-12. Retrieved 2010-04-10.
  39. ↑ "Rubella | Rubella in the United States". www.cdc.gov. Centers for Disease Control and Prevention. 2017-09-12. Archived from the original on 2018-12-07. Retrieved 2018-10-21.
  40. ↑ Plotkin SA (2001). "Rubella eradication". Vaccine . 19 (25–26): 3311–9. doi:10.1016/S0264-410X(01)00073-1. PMID   11348695.
  41. ↑ Cooper L (1975). "Congenital Rubella in the United States". In Krugman S Gershon A (ed.). Symposium on Infections Of the Fetus and Newborn Infant. New York: Alan R. Liss. pp. 1–. ISBN   978-0-8451-0003-5.
  42. ↑ Danovaro-Holliday MC, LeBaron CW, Allensworth C, et al. (2000). "A large rubella outbreak with spread from the workplace to the community". JAMA. 284 (21): 2733–9. doi: 10.1001/jama.284.21.2733 . PMID   11105178.
  43. ↑ Reef S (2006). "Rubella Mass Campaigns". Mass Vaccination: Global Aspects — Progress and Obstacles. Current Topics in Microbiology and Immunology. Vol. 304. pp. 221–9. doi:10.1007/3-540-36583-4_12. ISBN   978-3-540-29382-8. PMID   16989272.{{cite book}}: |journal= ignored (help)
  44. ↑ Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V (2021-11-22). "Vaccines for measles, mumps, rubella, and varicella in children". The Cochrane Database of Systematic Reviews. 2021 (11): CD004407. doi:10.1002/14651858.CD004407.pub5. ISSN   1469-493X. PMC   8607336 . PMID   34806766.
  45. ↑ Ujiie M, Nabae K, Shobayashi T (2014-04-26). "Rubella outbreak in Japan". The Lancet. 383 (9927): 1460–1461. doi: 10.1016/S0140-6736(14)60712-1 . ISSN   0140-6736. PMID   24766958. S2CID   2939503.
  46. 1 2 Ackerknecht EH (1982). A short history of medicine . Baltimore: Johns Hopkins University Press. pp.  129. ISBN   978-0-8018-2726-6.
  47. ↑ Wesselhoeft C (1949). "Rubella and congenital deformities". N. Engl. J. Med. 240 (7): 258–61. doi:10.1056/NEJM194902172400706. PMID   18109609.
  48. ↑ Best J, Cooray S, Banatvala J (2005). "45. Rubella". Topley and Wilson's Microbiology and Microbial Infections. Vol. 2 Virology. pp. 960–992. ISBN   978-0-340-88562-8.
  49. 1 2 3 Lee JY, Bowden DS (2000). "Rubella virus replication and links to teratogenicity". Clin. Microbiol. Rev. 13 (4): 571–87. doi:10.1128/CMR.13.4.571-587.2000. PMC   88950 . PMID   11023958.
  50. 1 2 3 4 Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. (2007). "12. Rubella" (PDF). Epidemiology and Prevention of Vaccine-Preventable Diseases (10th ed.). Centers for Disease Control and Prevention. Archived from the original on 2007-06-20. Retrieved 2007-07-03.
  51. 1 2 3 4 "Chapter 11 — Rubella" (PDF). Immunisation Handbook 2006. Ministry of Health, Wellington, NZ. April 2006. ISBN   978-0-478-29926-7. Archived from the original on 2007-11-15. Retrieved 2007-07-03.
  52. ↑ Smith JL (1881). "Contributions to the study of Rötheln". Trans. Int. Med. Congr. Phil. 4 (14).
  53. ↑ Hess AF (1914). "German measles (rubella): an experimental study". Archives of Internal Medicine. 13 (6): 913–6. doi:10.1001/archinte.1914.00070120075007. Archived from the original on 2020-08-06. Retrieved 2019-09-09. as cited by Enersen OD (1934). "Alfred Fabian Hess". Science. 79 (2039): 70–72. Bibcode:1934Sci....79...70.. doi:10.1126/science.79.2039.70. PMID   17798141. Archived from the original on 2007-09-30. Retrieved 2007-07-03.
  54. ↑ Reagan LJ (2010-07-20). Dangerous Pregnancies: Mothers, Disabilities, and Abortion in Modern America. University of California Press. p. 84. ISBN   978-0-520-94500-5. Archived from the original on 2023-01-13. Retrieved 2017-09-11.
  55. ↑ J.B. Hanshaw, J.A. Dudgeon, and W.C. Marshall. Viral diseases of the fetus and newborn. W.B. Saunders Co., Philadelphia, 1985
  56. ↑ "Public Health Burden of Rubella and CRS" (PDF). EPI Newsletter. XX (4). Pan American Health Organization. August 1998. Archived (PDF) from the original on 2011-07-19. Retrieved 2007-07-03.
  57. ↑ Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA (2015-06-06). "Rubella". Lancet. 385 (9984): 2297–2307. doi:10.1016/S0140-6736(14)60539-0. ISSN   0140-6736. PMC   4514442 . PMID   25576992.
  58. ↑ Best JM, Banatvala J, Almeida JD, Waterson A (29 July 1967). "Morphological Characteristics of Rubella Virus". The Lancet. 290 (7509): 237–239. doi:10.1016/S0140-6736(67)92302-1.
  59. ↑ "Colombia, libre de sarampión y rubéola – Archivo Digital de Noticias de Colombia y el Mundo desde 1.990 – eltiempo.com". 2014-01-22. Archived from the original on 2014-02-02.
  60. ↑ "Colombia fue declarada libre de sarampión y rubéola". 2014-01-22. Archived from the original on 2015-05-23.
  61. ↑ "Rubella (German measles) eradicated from Americas". BBC. April 29, 2015. Archived from the original on May 1, 2015. Retrieved April 30, 2015.
  62. ↑ Pommerville JC (2014). Fundamentals of Microbiology (10th ed.). Boston: Jones and Bartlett. p. 513. ISBN   978-1-284-03968-9.
  63. ↑ "Rubeola". Merriam-Webster.com. Archived from the original on 2009-04-21. Retrieved 2009-09-20.
  64. ↑ C TE Jr (January 1972). "Letters to the editor". Pediatrics. 49 (1): 150–1. doi:10.1542/peds.49.1.150a. PMID   5059301. S2CID   245076860. Archived from the original on 2021-08-29. Retrieved 2009-09-20.
  65. ↑ "rubella". Linguee.es. DeepL. Archived from the original on 8 October 2020. Retrieved 4 October 2020.
  66. ↑ "measles". Linguee.es. DeepL. Archived from the original on 8 October 2020. Retrieved 4 October 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.